Pharma: Other news to note
Thursday, January 23, 2014
Eisai Inc., of Woodcliff Lake, N.J., said the European Commission granted orphan drug status to amituximab, discovered and developed by Morphotek Inc., of Exton, Pa., a wholly owned subsidiary of Eisai, for malignant mesothelioma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.